Number10 e-Petition response

Number10.gov.uk The official site of the Prime Minister’s Office

e-Petition response

Shortlink: http://wp.me/p5foE-2Ld

http://petitions.number10.gov.uk/MEInquiry/#detail

This petition is now closed, as its deadline has passed.

Submitted by Dave Loomes – Deadline to sign up by: 17 September 2009 – Signatures: 316

Petition update, 05 February 2010

The Prime Minister’s Office has responded to that petition. The response can be viewed here and is also appended.

http://www.number10.gov.uk/Page22366

More details from petition creator

The All Party Parliamentary Group’s Gibson Inquiry into ME in 2006 came to the conclusion that it was highly inappropriate for psychiatrists such as Simon Wessely and Peter White et al to act as advisor’s on illnesses like ME CFS for the Government and the DWP while working as consultants for the medical insurance industry for companies such as UNUM Provident. The insurance industry have a clear vested interest in classifying such illnesses as psychiatric conditions (despite the WHO classification of ME as a neurological condition ICD 10 G93.3) since they have to pay out less on policies.

The recommendations of the Gibson Inquiry called for an appropriate standards body to be set up to investigate these clear and alarming vested interests. This recommendation seems to have disappeared in a puff of smoke?

We the undersigned call for a immediate public inquiry into these inappropriate and blatant conflicts of interest!

Dave Loomes, the Petition Creator

Response published Friday 5 February 2010

http://www.number10.gov.uk/Page22366

E-petition response

We received a petition asking:

“We the undersigned petition the Prime Minister to take up Gibson Inquiry into ME recommendation of a Public Inquiry into vested interests.”

Details of Petition:

“The All Party Parliamentary Group’s Gibson Inquiry into ME in 2006 came to the conclusion that it was highly inappropriate for psychiatrists such as Simon Wessely and Peter White et al to act as advisor’s on illnesses like ME CFS for the Government and the DWP while working as consultants for the medical insurance industry for companies such as UNUM Provident. The insurance industry have a clear vested interest in classifying such illnesses as psychiatric conditions (despite the WHO classification of ME as a neurological condition ICD 10 G93.3) since they have to pay out less on policies. The recommendations of the Gibson Inquiry called for an appropriate standards body to be set up to investigate these clear and alarming vested interests. This recommendation seems to have disappeared in a puff of smoke? We the undersigned call for a immediate public inquiry into these inappropriate and blatant conflicts of interest!.”

Read the Government’s response

The independent inquiry mentioned in your petition stems from a report published in 2006. Neither the Department of Health nor the Department for Work and Pensions (DWP) were involved in producing the report and have no plans to respond to its findings. The recommendations in the report have since been surpassed by updated guidance from the National Institute for Health and Clinical Excellence for the management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).

Professors Peter White and Simon Wessely hold Chairs in Psychological Medicine at London University. They have an international reputation in the clinical management of and research into several medical subjects, which include CFS/ME. As such, many organisations including government Departments will draw on their expertise. These doctors have been asked to provide factual clinical information about medical conditions and have no interest in the outcome of state benefit decisions or those made by the insurance industry. They have an ethical obligation to provide advice to the best of their knowledge and the Government is confident that they have done this in their advice to Departments.

Professor White has advised DWP in the development of guidance for Disability Living Allowance Decision Makers in a number of psychiatric conditions. He has also provided medical advice on CFS/ME and other related medical conditions. In addition to Professor White, DWP has also consulted with other medical experts with an interest in this condition including a rheumatologist, immunologist, occupational therapist, rehabilitation specialist, and physiotherapist. The guidance was also reviewed and discussed extensively with ME charities, welfare rights groups and their medical advisers who provided many helpful comments, which were included in the guidance wherever possible.

Professor White has provided his independent medical expertise to the insurance industry to help them to understand the medical issues when considering developing policies and deciding claims. As far as UNUM is concerned he has only ever attended one meeting organised by UNUM several years ago, but only as an independent specialist. This involvement in no way compromises the expert medical advice given to the Department, and his insurance consultancy work has always been known to the Department.

Professor Simon Wessely has not been involved in the development of CFS/ME guidance but has advised with guidance developed for some psychiatric conditions. He has served as a member of Dame Carol Black’s working group on employment. As far as UNUM is concerned Professor Wessely has not given advice, but has spoken at two UNUM sponsored medical meetings.

The term Chronic Fatigue Syndrome (CFS) is used to describe an illness that is characterised by physical and mental fatigue and fatigability.

A characteristic feature is fatigue/malaise that follows minimal exertion. People with CFS often describe the fatigue as being of a type and a scale beyond any other they have experienced. The illness may affect both physical and mental functioning, including cognitive function. Accompanying symptoms may include poor sleep, pain, poor concentration and memory, although this list is not exhaustive.

CFS is also known as Myalgic Encephalomyelitis (ME) and post-viral fatigue syndrome. There is some difference of opinion over whether ME is different from CFS; however, most authorities refer to the condition as CFS/ME.

CFS/ME is identified by its symptoms and disabling effects, and by excluding other medical conditions that could explain them. There are no confirmatory abnormal findings on physical examination, nor is there any specific investigation such as an abnormal blood test that is diagnostic. This does not mean that CFS/ME is not a real illness.

The classification of CFS/ME is confusing and controversial since there are five different World Health Organisation categories that could be chosen by a doctor to describe the illness. The Department of Health classifies the illness as neurological (G93.3). Since eligibility to State Benefits depends more on the severity and nature of disability and its effects, rather than the particular diagnosis, this issue is not central to the guidance developed by DWP. For the purpose of Disability Living Allowance the current law means that a claimant cannot be eligible for a higher rate of mobility unless his/her disability is considered “physical.” For this purpose, CFS/ME is classified as “physical.”

 

This petition had not to my knowledge been widely circulated. Had it been brought to my attention with a view to my promoting it on this site, I would have alerted the petition’s creator to the following and suggested that the wording of the petition might be amended.

Had the creators of this e-Petition checked the Register of All-Party Groups before submitting their petition, they would have established the correct name and status of the group which undertook the “Gibson Inquiry”.

The All-Party Parliamentary Group on ME was not responsible for undertaking the “Gibson Inquiry” or publishing the “Gibson Report”.

This unofficial inquiry had been undertaken by an ad hoc group set up by former MP, Dr Ian Gibson, specifically to carry out the “inquiry” because Dr Gibson had been unable to achieve the instigation of the “full”, “high level” and “independent” inquiry he had been seeking within the very short time frame he had set for himself.

Dr Gibson chaired the panel, himself, and it was Dr Gibson who decided whom he would invite onto his panel.

It is the case that the “Gibson Inquiry” panel included some office holders of the APPG on ME and others associated with it. But the inquiry was undertaken independently of the APPG on ME and it did not report to the APPG on ME, in the sense that it was accountable to the APPG on ME, it was accountable only to itself.

The group was registered with the Office of the Parliamentary Commissioner for Standards as “The Group on Scientific Research into ME” (GSRME). 

Most, but not all, groups are on the “Approved List” of All-Party Parliamentary Groups and Associate Parliamentary Groups. The Group on Scientific Research into ME was not on the “Approved List”.

Because of its registration status, under the Rules on All-Party Groups the GSRME group was bound by different requirements for its convening and different rules for its operation, one rule being that it was not permitted to refer to itself as an “All-Party Parliamentary Group”. 

In January 2007, Philippa Wainwright, Office of the Parliamentary Commissioner for Standards clarified that:

“Because the group is on the Register of All-Party Groups it is entitled to use the House emblems (eg the Portcullis) on any of its documents (eg reports, press notices, agendas) and on its website, and it is also allowed to give ‘House of Commons’ as its address on its letterhead.

“However, groups that are not on the Approved List are not allowed to use the terms ‘All-Party’, ‘Associate’ or ‘Parliamentary’ in their title, In the light of what you say, I shall write to the group reminding them of the rules on this point.”

And clarifying the authority of the report that was e-published, only, by the GSRME, in November 2006, Ms Wainwright wrote:

“In parliamentary terms all-party groups have no official status, and are viewed as informal. Their reports therefore have only the authority of those who produce them.”

In terms of status, then, the GSRME sat on the lowest rung of parliamentary groups beneath that of All-Party groups.

The group disbanded in May 2007.

A pro bono website was placed at the disposal of the group which remains online, drifting like the Marie Celeste, here:  http://www.erythos.com/gibsonenquiry/

The APPG on ME’s website is this one:  http://www.appgme.org.uk/

 

The more recent inquiry into NHS service provision for people with ME, chaired by Dr Des Turner (who will be standing down at the election, and thus from office of chair to the APPG on ME) was undertaken by the APPG on ME.

This inquiry has published only an “interim” document and it remains unclear whether it intends to publish a final report before the group is dissolved at the forthcoming election (as all All-Party Groups will be).

If the APPG on ME is to continue beyond the election, a new group with a new chair and a new committee with 20 “Qualifying Members” (parliamentarians) will need to be convened.

As with the NHS service provision inquiry, the “Gibson Inquiry” was an unofficial inquiry.

The report that came out of the “Gibson Inquiry” does not have the authority of either House of Parliament nor any government department; it was not a commissioned inquiry nor the product of a select committee, standing committee or any other Parliamentary Committee.  It had no funding, no dedicated administrative staff or resources and as stated above, was accountable only to itself. 

It is incorrect to refer to the “Gibson Inquiry” as a “Parliamentary Inquiry”, a “government report” or an “official report” since it is none of these: no department or minister was obliged to respond to its recommendations and Dr Gibson and his panel received no responses to their report.

The APPG on ME had planned to try and secure the interest a select committee in its findings and recommendations for its own inquiry into NHS service provision. But only a very brief document has thus far been circulated by the APPG on ME chair (and note, not as a document for comment or discussion).

 

The Secretary to the GSRME resigned the day after the report was published. The group began to disassemble and formally disbanded in May 2007.

The No 10 e-Petition Response notes that:

“For the purpose of Disability Living Allowance the current law means that a claimant cannot be eligible for a higher rate of mobility unless his/her disability is considered ‘physical.’ For this purpose, CFS/ME is classified as ‘physical.’”

The “Gibson Report” got this wrong (and there were other errors in the report).

In January 2007, Dr Gibson held a public meeting in London to discuss the content of the report and how it might be used as a campaigning tool. Dr Charles Shepherd (ME Association) and other national patient organisations and advocates had brought a number of significant errors, misconceptions, contradictions, omissions and ambiguities to the attention of Dr Gibson and what remained of his panel. Dr Gibson argued the toss over the issue of the panel’s misconception over entitlement to higher rate DLA, but he did eventually agree that the error the panel had made in its report would be corrected and that other problems with the report would be attended to. (Unofficial Transcript: Public Meeting of the GSRME, January 07)

But it was not corrected: once the public meeting to discuss the content of the report had been held, Dr Gibson was unable to get his panel to discuss making any amendments and the report remains entirely unamended. This misconception over higher rate DLA by the “Gibson panel” has been reiterated by the press on several occasions.

When drawing up the inquiry’s Terms of Reference, no procedures had been put in place by the panel for dealing with errors in the report; it was published without consultation and sent out to 600 odd MPs, to the Chief Medical Officer and various government ministers, complete with errors, before the ME community and ME patient organisations had had sight of it.

When it comes to inquiries be careful what you wish for.

I may comment at a later date on the content of the Number10 Response.

ME Association not prepared to confirm source of XMRV “prostate cancer” test information

The ME Association is not prepared to confirm the source of its XMRV “prostate cancer” test information

Shortlink: http://wp.me/p5foE-2Ll

On 6 February, the ME Association put out the following notice:

 http://tinyurl.com/MEAonICLXMRVtest

“Late last night The ME Association was informed that this announcement about XMRV testing does not apply to people with ME/CFS, or suspected ME/CFS. It only relates to the availability of the Imperial College XMRV test to referring doctors who are dealing with cases of prostate cancer. A full clarification will appear on the Imperial College website on Monday. It will appear here once we have it.”

Note no source for this information.

This morning, Imperial College, London, took down its XMRV Testing webpages and published this notice:

Imperial College London  XMRV Testing Notification

XMRV testing

We wish to apologise for any confusion concerning the availability of this test and would like to clarify that it is only available as part of an ethically approved research project. We emphasis that our laboratory does not deal directly with patients and we are not advising people who are concerned that they might have CFS, or who have been diagnosed with CFS, to request this test.

Note no “full clarification” and no explanation of the specific purpose for which this test is intended  - only that it is “only available as part of an ethically approved research project” and that Imperial College is “not advising people who are concerned that they might have CFS, or who have been diagnosed with CFS, to request this test.”

So, a test for detection of XMRV in what, precisely?

On Sunday, I emailed Tony Britton, ME Association Press and PR, with a request that the ME Association clarifies the source of its information that:

“It only relates to the availability of the Imperial College XMRV test to referring doctors who are dealing with cases of prostate cancer.”

No response.

A few minutes ago, I telephoned Tony Britton for clarification. Mr Britton says he is not prepared to “reveal his sources”.

I asked Mr Britton if he would confirm or deny whether the information came directly from Imperial College.  He will not.

I asked Mr Britton if he would confirm or deny whether the information came directly from Professor Simon Wessley.  Again, Mr Britton was not prepared to confirm or deny, and abruptly terminated the call.

Given the paucity of information contained within the notification issued by Imperial College, this morning, speculation if rife.

The ME Association is evidently not prepared to be transparent.  How then, without knowing the source, can we decide whether this information might be relied upon or not?

Perhaps in future, if the ME Association is unwilling to provide verifiable sources for information such as this (which is in the public interest) it should think very hard about whether it should be prepared to put that information out in the first place.

So who is the ME Association acting as a spokesperson for?

And why is Imperial College not prepared to be transparent about the purpose of this test?

Important statement from Imperial College, London (XMRV Detection Testing)

Important statement from Imperial College, London (XMRV Detection Testing)

Shortlink: http://wp.me/p5foE-2Li

(Please note that all the pages for the XMRV Testing were off line at 11.15am GMT)

Imperial College webpage:

Imperial College London  XMRV Testing Notification

XMRV testing

We wish to apologise for any confusion concerning the availability of this test and would like to clarify that it is only available as part of an ethically approved research project. We emphasis that our laboratory does not deal directly with patients and we are not advising people who are concerned that they might have CFS, or who have been diagnosed with CFS, to request this test.

The Prof Wessely XMRV Detection Test exchanges

The Professor Wessely XMRV Detection Test exchanges

Shortlink: http://wp.me/p5foE-2KS

This report may be reposted provided it is published in full, unedited and http://meagenda.wordpress.com is credited as the source.

Compiled by Suzy Chapman  |  7 February 2010

On 4 February, it was widely reported around the internet that the Molecular Diagnostics Unit, Imperial College, London, is now offering XMRV Detection Testing. All the available information on this £200 test, as it currently stands on Imperial College website, is published in this posting:

Complete text of Imperial College, London XMRV Detection Testing web pages (06.02.10)

In January, a study published by PLoSOne, and led by Prof Myra McClure of Imperial College, had reported that its authors found no evidence that XMRV is associated with CFS in the UK.

The study concluded:

“Based on our molecular data, we do not share the conviction that XMRV may be a contributory factor in the pathogenesis of CFS, at least in the U.K.”

and

“XMRV or MLV sequences were not amplified from DNA originating from CFS patients in the UK. Although we found no evidence that XMRV is associated with CFS in the UK, this may be a result of population differences between North America and Europe regarding the general prevalence of XMRV infection, and might also explain the fact that two US groups found XMRV in prostate cancer tissue, while two European studies did not.”

On 5 February, a member of the ME community, Fiona Verity, contacted Professor Simon Wessely, one of the co- authors of the paper: Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare A. (2010) Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One. 2010; 5: e8519Full paper

Prof Wessely is acknowledged in the paper as having been responsible for “providing samples and associated data from a well characterised and valuable cohort of subjects.”

[Cohort = 186 patients (62% female, age range 19-70, mean 39.6±11.3 years) from consecutive referrals to the CFS clinic at King's College Hospital, London.]

On 5 February, the ME Association issued this position statement:

ME Association  |  05 February 2010

XMRV testing at Imperial College, London

Imperial College, the research centre in the UK that has found no evidence of XMRV infection in any of the blood samples from people with ME/CFS that they have looked at, has announced that their Molecular Diagnostics Unit is now offering their method for XMRV testing to the public: Imperial College announcement

 MEA POSITION STATEMENT

Until we have the results from more replication studies the link between XMRV and ME/CFS remains speculative and unproven. We do not therefore believe that there is any point in spending money on an expensive blood test which is not, at present, going to act as either a diagnostic marker or an aid to management. And any laboratory offering this test to the public has an ethical duty to make these points clear.

We would, however, be interested to hear from anyone in the UK who does decide to have an XMRV test.

The latest MEA summary on XMRV can be found here

A summary of the Imperial College research which looked for XMRV in ME/CFS can be found here

We hope that the situation regarding XMRV and ME/CFS will become clear once results from the other replication studies appear in the scientific journals over the coming months.

On 6 February, the ME Association published this notice: http://tinyurl.com/MEAonICLXMRVtest

“Late last night The ME Association was informed that this announcement about XMRV testing does not apply to people with ME/CFS, or suspected ME/CFS. It only relates to the availability of the Imperial College XMRV test to referring doctors who are dealing with cases of prostate cancer. A full clarification will appear on the Imperial College website on Monday. It will appear here once we have it.”

The ME Association does not specify the provenance of this information.

When Imperial College does publish a clarification I will post an update at the top of this posting.

There has been much confusion about the purpose of this test and the patient population(s) that might be referred for it.

Questions have also been raised around the specific testing methods being used in relation to XMRV and its possible association with prostate cancer or suspected prostate cancer. Other laboratories have found XMRV in prostate tumour and tumour-associated tissues only, not in whole blood samples as specified by Imperial College. (References [1], [2] and [6], Imperial College website text.)

Ms Verity has very kindly given permission to publish in full the email exchange between herself and Professor Wessely.

From: Fiona Verity
Sent: 05 February 2010 16:57
To: Zielona, Olga
Subject: F.A.O Prof Wessley please forward

Dear Professor Wessley,

I am aware that the XMRV test is to be made available for purchase. I am concerned about this and would be grateful if you would read the following email that I have sent to ME agenda (below). I hope you will understand that there are many very vulnerable people aware of the research into an illness that is crippling their lives. Whilst you and your colleagues I am sure have their best interests at heart I fail to see why you are now offering this test to CF/ME sufferers and furthermore they will be charged.

Your own research failed to detect the XMRV virus yet you are going to sell this test for £200 to the very people that your research results concluded will not have this virus. I feel I must have misunderstood the thread of all this somewhere and I hope you will take the time to reply; my main question at this point is, do you expect the XMRV virus to now be detected in these tests perhaps through a different approach, if so what will you be doing with the findings and if not is there a benefit to be had by those paying and having the test?

Your advice is keenly awaited.

Thank you

Fiona Verity MSc

5th February 2010

To Whom It May Concern,

As I understand it the research for the connection between CF and XMRV virus tests according to Kings College were inconclusive. Furthermore, it appears questionable that this UK study can be compared with the major research and findings carried out in the US, as the exact conditions were not replicated and therefore one would expect different outcome measures. From what I understand it the very approach offered by Kings College for the process/testing of XMRV is flawed in-as-much as their controls do not replicate the procedures and protocols applied in the US therefore suggesting that King’s College research would fail to detect the XMRV virus.

Needless-to-say I am concerned that you are now making this same XMRV test available to ME/CF patients because it appears that this will be wasting their money – unless of course the testing approach has been altered to replicate US study and test? Secondly if the test is the same as that used in Kings College’s initial research then these results from the new tests paid for by CF/ME sufferers will go further to ‘falsely’ supporting inconclusive outcome result of Kings College’s own research.

I urge you therefore to look further into the matter so as not to afford a disservice to those you wish to assist i.e. ME/CF sufferers not to mention the devastating consequences of supporting research that could indeed be harmful to further much needed research in the field.

However, if I have misunderstood any element of this I look forward to an explanation at your earliest convenience.

Your faithfully

F. Verity MSc

 

From: Wessely, Simon
Date: 5 February 2010 18:26
Subject: RE: F.A.O Prof Wessley please forward
To: Fiona Verity

Thank you for your inquiry re the announcement from Imperial College that they are offering a diagnostic test for XMRV

I understand that this is not intended for people who know they have CFS or are concerned they might have CFS

I can see that this is not clear from the announcement though, but it seems this was an oversight which is going to be speedily corrected

I hope this clarifies matters

Simon Wessely

Professor Simon Wessely
Vice Dean, Institute of Psychiatry,
Head, Department of Psychological Medicine,
Director, King’s Centre for Military Health Research,
King’s College London

Imperial College website content as it stood at 6 February 10

Complete text of Imperial College, London XMRV Detection Testing web pages

Shortlink: http://wp.me/p5foE-2K1

Complete text of Imperial College, London XMRV Detection Testing web pages

Complete text of Imperial College, London XMRV Detection Testing web pages

Shortlink: http://wp.me/p5foE-2K1

Today, 6 February, the ME Association has published the following statement

“Late last night The ME Association was informed that this announcement about XMRV testing does not apply to people with ME/CFS, or suspected ME/CFS. It only relates to the availability of the Imperial College XMRV test to referring doctors who are dealing with cases of prostate cancer. A full clarification will appear on the Imperial College website on Monday. It will appear here once we have it.”

On 5 February, Professor Simon Wessely’s office had responded to an enquirer that it was Professor Wessely’s understanding that this Imperial College test “is not intended for people who know they have CFS or are concerned they might have CFS”, that he could see that “it was not clear from the announcement”, that “it seems this was an oversight which is going to be speedily corrected” and that he hoped this clarified matters.

Professor Wessely was a co-author of the January 2010 paper: Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare A. (2010) Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One. 2010; 5: e8519.  Full text PLoSOne paper

This study, led by Prof Myra McClure of Imperial College London, found no evidence that XMRV is associated with CFS in the UK.

Professor Wessely is Vice Dean, Institute of Psychiatry, Head of Department of Psychological Medicine, Director, King’s Centre for Military Health Research, King’s College London. Since Professor Wessely is employed by the Institute of Psychiatry, it is unclear why he has taken it upon himself to act as a spokesperson for the Molecular Diagnostics Unit, Imperial College, London.

There has been much confusion about the purpose of this test and the patient population(s) that might be referred for the test. Questions have also been raised around the specific testing methods being used in relation to XMRV and its possible association with prostate cancer or suspected prostate cancer. Other laboratories have found XMRV in prostate tumour and tumour-associated tissues only, not in whole blood samples as specified by Imperial College.
(References [1], [2] and [6], Imperial College website text)

As the Imperial College webpages are anticipated to be updated next week in order to address the lack of clarity, I am publishing, for the record, copies of all text currently available on the Imperial College website that relates to the offering of this test.

—————

All text and Word document accessed on 06.02.10

http://tinyurl.com/XMRVDetectionTesting

This is Google’s cache of  http://tinyurl.com/XMRVDetectionTesting as the web page appeared on 27 Jan 2010 16:00:45 GMT.

Imperial College, London
Faculty of Medicine

XMRV Detection Testing

Scope of the test
Infection with the newly discovered retrovirus xenotropic murine leukaemia virus-related virus (XMRV) has been associated with prostate cancer [1, 2] and chronic fatigue syndrome (CFS) [3]. No causal link between infection and any human disease has been proven and the association between XMRV and prostate cancer or CFS remains controversial [4-6]. Indeed, in a study in our own laboratory of 186 patients with well-defined CFS we failed to detect the virus in any sample [7].

Test details (top of page)
The test uses the polymerase chain reaction (PCR) to detect XMRV provirus (the DNA form of the viral genome) in peripheral blood mononuclear cells. The limit of detection of the method is one XMRV proviral DNA copy in 105 cells. The test includes controls for non-specific inhibition of PCR to avoid false negative results. The method is a fully validated in-house method. A summary of the validation is available from the Unit Manager.

Reporting results (top of page)
The results will be reported as “XMRV detected” or “XMRV not detected”, the test is not quantitative at present.

Turnaround time (top of page)
We aim to issue reports within two weeks of receiving a sample. Details of samples and sample shipment are given on the user instruction page [weblink]. Please note we can only accept test requests and samples from medical practitioners (GPs or hospital doctors) we will not accept test requests directly from patients.

Charges (top of page)
The current charge for testing is £200/sample.

Complaints (top of page)
If you are unhappy with the service provided by MDU or if you wish to make suggestions on how our service can be improved, please contact the Unit Manager.

References (top of page)

1.Urisman A, Molinaro RJ, Fischer N Plummer SJ, Casey G et al. (2006) Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNaseL variant. PLoS Pathog. 2: 211- 225.
2.Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR (2009) XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumours. Proc Natl Acad Sci U S A. 106: 16351-6
3.Lombardi V, Ruscetti FW, Gupta JD, Pfost MA, Hagen KS et al. (2009) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326: 585-589.
4.Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H et al. (2008) Prevalence of human gamma retrovirus XMRV in sporadic prostate cancer. J Clin Virol. 43: 277-283.
5.D’Arcy FR, Foley A, Perry L, Marignol L, Lawler M et al. (2008) No evidence of XMRV in Irish prostate cancer patients with the R462Q mutations. European Urology 7 Suppl: 271
6.Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N et al. (2009) Lack of evidence for xenotropic murine leukemia virus-related virus (XMRV) in German prostate cancer patients. Retrovirology 6:92.
7.Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare A. (2010) Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One. 2010; 5: e8519.

—————

This is Google’s cache of http://tinyurl.com/XMRVuserinstructions as the web page appeared on 6 Feb 2010 19:11:36 GMT.

http://tinyurl.com/XMRVuserinstructions

First time users

For routine testing, the required sample is one 4.5ml EDTA Vacutainer of whole blood.

Each sample must be accompanied by a Request Form. This can either be the form provided by MDU or your own form. If it is the latter it must contain the following details:

•  patient clinic number (not the patient’s name)
• date of birth
• sample date
• reason for requesting the test

Samples should be couriered or mailed to MDU on the day of collection if possible.

If it is not possible to ship the sample the same day it can be kept in the refrigerator (not freezer) and shipped the next day or can be shipped the following Monday if taken on Friday.

The shipper is responsible for packaging the sample according to current guidelines for shipment of pathology specimens.

First time users

If you are using the service for the first time please contact the Unit manager, Dr Steve Kaye, to discuss your requirements and answer any questions you may have.

Email: steve.kaye@imperial.ac.uk
Tel: 020 759 43917 (direct)

Delivery address

FAO Dr Steve Kaye
Molecular Diagnostic Unit,
Imperial College London
4th Floor, Medical School Building
St. Mary’s Hospital
Norfolk Place
London W2 1PG

Test Request Form

http://tinyurl.com/XMRVTestRequestForm or

http://wwwfom.sk.med.ic.ac.uk/resources/543939B5-003D-4709-B6EC-238FC0D5502F/

Open Word document here on ICL site: ICL Test Request Form

Open Word document here on ME agenda: ICL Test Request Form

Text of Request Form

Imperial College London

MDU
Molecular Diagnostics Unit
Imperial College London
Jefferiss Trust Laboratory, St Mary’s Campus, Norfolk Place
London W2 1PG
Tel. +44 (0) 207 5943 917

Please send one 4.5ml EDTA Vacutainer to: Dr Steve Kaye, Molecular Diagnostics Unit, 4th floor Medical School Building, St. Mary’s Hospital, Norfolk Place, London W2 1PG.

The shipper is responsible for packaging the sample in accordance with current guidelines for the shipment of pathology specimens.

Note we will only accept requests from doctors or clinics, not directly from patients.

Patient details (sticker)

Clinic number_________________________ Sample date________________________

Date of birth_________________________

Reason for request:

Request from/report to: Doctor_____________________________________

Centre/Clinic________________________________

Address____________________________________
____________________________________
Tel___________________email_________________

Telegraph: Letters to the Editor: Breaking the ME enigma (jointly signed by ME spokespersons)

Telegraph: Letters to the Editor: Breaking the ME enigma (jointly signed by ME spokespersons)

Shortlink: http://wp.me/p5foE-2JX

Telegraph  |  06 February 2010

Breaking the ME enigma

SIR – The death of Lynn Gilderdale and the humane verdict in the trial of her mother brought home to many people for the first time what a devastating illness myalgic encephalomyelitis (ME) can be.

Many of the estimated quarter of a million people with ME in Britain experience not only extreme pain and disability, but also incomprehension, ignorance, lack of sympathy and at times outright hostility, not only from the public but also from professionals responsible for their care.

Such lack of understanding even extends to blaming parents for the severity of their child’s illness.

It is time the nation began to take ME seriously. Provision of adequate clinical and other services by properly informed and sympathetic professionals is currently subject to a postcode lottery. Such provision should avoid inappropriate treatments, and range from support for home tuition for school-age children to respite care for the severely affected.

Above all, we should fund biomedical research to resolve the enigma of the underlying pathology of this illness. We should build on recent scientific advances to develop effective treatments, so that no one in future need experience the pain, isolation and despair that were Lynn Gilderdale’s fate.

Countess of Mar
Secretary, All Party Parliamentary Group on ME
Dr Neil Abbot
Operations Director, ME Research UK
Jane Colby
Executive Director, The Young ME Sufferers Trust
Anne Faulkner
Hon Director, CFS Research Foundation
Tanya Harrison
Chairman, BRAME
Malcolm Hooper
Emeritus Professor of Medicinal Chemistry, University of Sunderland
Andy Kerr MSP
Dr Jonathan Kerr
Consultant Senior Lecturer, St George’s, University of London
Simon Lawrence
Chairman, 25 per cent ME Group
Kathleen McCall
Chairman, Invest in ME
Dr Luis Nacul
Consultant in Public Health, London School of Hygiene and Tropical Medicine Professor
Derek Pheby
National ME/CFS Observatory
Neil Riley
Chairman, ME Association
Dr Charles Shepherd
Dr Nigel Speight
Sir Peter Spencer
Chief Executive Officer, Action for ME
Des Turner MP
Chairman, All Party Parliamentary Group on ME
Dr William Weir
Mary-Jane Willows
Chief Executive Officer, Association of Young People with ME
Andrew Stunell MP
Vice Chairman, All Party Parliamentary Group for ME

Announcement about XMRV testing at Imperial College, London

Announcement about XMRV testing at Imperial College, London

Shortlink: http://wp.me/p5foE-2JV

ME Association  |  06 February 2010

IMPORTANT UPDATE – SATURDAY 6th FEBRUARY

Late last night The ME Association was informed that this announcement about XMRV testing does not apply to people with ME/CFS, or suspected ME/CFS.

It only relates to the availability of the Imperial College XMRV test to referring doctors who are dealing with cases of prostate cancer.

A full clarification will appear on the Imperial College website on Monday. It will appear here once we have it.

Dr Charles Shepherd

Hon Medical Adviser, MEA

BBC accused of ‘promoting euthanasia by ignoring rights of disabled’

BBC accused of ‘promoting euthanasia by ignoring rights of disabled’

Shortlink: http://wp.me/p5foE-2JR

Telegraph  |  05 February 2010

BBC accused of ‘promoting euthanasia by ignoring rights of disabled’

The BBC has been accused of promoting euthanasia by a cross-party group of MPs who called on ministers to threaten to cut off the supply of public money to the broadcaster.

A Commons motion highlighted the high profile given by the BBC to author Sir Terry Pratchett’s speech in favour of assisted suicide Photo: BBC

A Commons motion said the Corporation ”misused public funds” in its coverage of the issue, highlighting the high profile given to author Sir Terry Pratchett’s speech this week in favour of assisted suicide.

The motion claimed the BBC ”ignored the rights of the disabled” and had used drama as well as news to promote its pro-euthanasia stance.

Tory Ann Winterton (Congleton) has the support of one Tory and four Labour MPs for her early day motion…

Read on here Telegraph 

Guardian  |  4 February 2010

‘Kay Gilderdale should have been investigated’

In cases of assisted dying, anyone involved should have to account for their actions, says Phil Friend

Like a lot of other people I watched Panorama on Monday evening which focused on the subject of assisted dying. The central issue concerned whether Kay Gilderdale should have been prosecuted for assisting her daughter Lynn to die…

Read on here Guardian

ME Association position statement: XMRV testing at Imperial College, London

ME Association position statement: XMRV testing at Imperial College, London

Shortlink: http://wp.me/p5foE-2JL

Following an extraordinary move by Imperial College, London to offer testing for XMRV infection at £200 a pop (ICL must be very confident their test will return no positives), the ME Association issues a position statement:

ME Association  |  05 February 2010

XMRV testing at Imperial College, London

Imperial College, the research centre in the UK that has found no evidence of XMRV infection in any of the blood samples from people with ME/CFS that they have looked at, has announced that their Molecular Diagnostics Unit is now offering their method for XMRV testing to the public: Imperial College announcement

MEA POSITION STATEMENT

Until we have the results from more replication studies the link between XMRV and ME/CFS remains speculative and unproven. We do not therefore believe that there is any point in spending money on an expensive blood test which is not, at present, going to act as either a diagnostic marker or an aid to management. And any laboratory offering this test to the public has an ethical duty to make these points clear.

We would, however, be interested to hear from anyone in the UK who does decide to have an XMRV test.

The latest MEA summary on XMRV can be found here

A summary of the Imperial College research which looked for XMRV in ME/CFS can be found here

We hope that the situation regarding XMRV and ME/CFS will become clear once results from the other replication studies appear in the scientific journals over the coming months.

Imperial College London to offer £200 XMRV test

Imperial College London to offer £200 XMRV test! 

Shortlink: http://wp.me/p5foE-2Jx

Entry Word: chutzpah
Function:
noun
Meaning:
also chutzpa or hutzpah or
hutzpa
shameless boldness — see
EFFRONTERY

Having published, last month, in PloS One, that a study led by Prof Myra McClure (Imperial College London) and Prof Simon Wessely (King’s College London) found no evidence that XMRV is associated with CFS in the UK, Imperial College London is now offering a £200 XMRV test.

Related material:

Failure to Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome

Abstract and links for full paper: http://wp.me/p5foE-2Bd
Media coverage Round up 1: http://wp.me/p5foE-2Bj
Patient organisation responses Round up 2: http://wp.me/p5foE-2BA

Imperial College London News Release PDF: Imperial College London News Release XMRV

Failure to Detect the Novel Retrovirus XMRV in Chronic Fatigue Syndrome

Otto Erlwein¹, Steve Kaye¹, Myra O. McClure¹*, Jonathan Weber¹, Gillian Wills¹, David Collier², Simon Wessely³, Anthony Cleare³

1 Jefferiss Research Trust Laboratories, Section of Infectious Diseases, Wright-Fleming Institute, Faculty of Medicine, Imperial College London, St Mary’s Campus, Norfolk Place, London, United Kingdom, 2 Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry (King’s College London) De Crespigny Park, Denmark Hill, London, United Kingdom, 3 Department of Psychological Medicine, Institute of Psychiatry, King’s College London, Camberwell, London, United Kingdom

Imperial College London XMRV Detection testing

Scope of the test

Infection with the newly discovered retrovirus xenotropic murine leukaemia virus-related virus (XMRV) has been associated with prostate cancer [1, 2] and chronic fatigue syndrome (CFS) [3]. No causal link between infection and any human disease has been proven and the association between XMRV and prostate cancer or CFS remains controversial [4-6]. Indeed, in a study in our own laboratory of 186 patients with well-defined CFS we failed to detect the virus in any sample [7].

Test details

The test uses the polymerase chain reaction (PCR) to detect XMRV provirus (the DNA form of the viral genome) in peripheral blood mononuclear cells. The limit of detection of the method is one XMRV proviral DNA copy in 105 cells. The test includes controls for non-specific inhibition of PCR to avoid false negative results. The method is a fully validated in-house method. A summary of the validation is available from the Unit Manager.

Reporting results

The results will be reported as “XMRV detected” or “XMRV not detected”, the test is not quantitative at present.

Turnaround time

We aim to issue reports within two weeks of receiving a sample. Details of samples and sample shipment are given on the user instruction page [weblink]. Please note we can only accept test requests and samples from medical practitioners (GPs or hospital doctors) we will not accept test requests directly from patients.

Charges

The current charge for testing is £200/sample.

Complaints

If you are unhappy with the service provided by MDU or if you wish to make suggestions on how our service can be improved, please contact the Unit Manager.

References

1.Urisman A, Molinaro RJ, Fischer N Plummer SJ, Casey G et al. (2006) Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNaseL variant. PLoS Pathog. 2: 211- 225.
2.Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR (2009) XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumours. Proc Natl Acad Sci U S A. 106: 16351-6
3.Lombardi V, Ruscetti FW, Gupta JD, Pfost MA, Hagen KS et al. (2009) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 326: 585-589.
4.Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H et al. (2008) Prevalence of human gamma retrovirus XMRV in sporadic prostate cancer. J Clin Virol. 43: 277-283.
5.D’Arcy FR, Foley A, Perry L, Marignol L, Lawler M et al. (2008) No evidence of XMRV in Irish prostate cancer patients with the R462Q mutations. European Urology 7 Suppl: 271
6.Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N et al. (2009) Lack of evidence for xenotropic murine leukemia virus-related virus (XMRV) in German prostate cancer patients. Retrovirology 6:92.
7.Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare A. (2010) Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One. 2010; 5: e8519.

Test Request Form

Open Word document here on ICL site: ICL Test Request Form

Open Word document here on ME agenda: ICL Test Request Form